Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/bcl-2-in-prostate-cancer-a-minireview-c27iFkd0Ml
References (115)
-
G. Narla, K. Heath, H. Reeves, Dan Li, L. Giono, Alec Kimmelman, M. Glucksman, J. Narla, F. Eng, A. Chan, A. Ferrari, J. Martignetti, S. Friedman (2001)
KLF6, a Candidate Tumor Suppressor Gene Mutated in Prostate CancerScience, 294
-
Moshe Shalev, T. Thompson, D. Kadmon, Gustavo Ayala, Kenneth Kernen, B. Miles (2001)
Gene therapy for prostate cancer.Urology, 57 1
-
S. Haldar, J. Chintapalli, C. Croce (1996)
Taxol induces bcl-2 phosphorylation and death of prostate cancer cells.Cancer research, 56 6
-
M. Davies, S. Kim, N. Parikh, Z. Dong, C. Bucana, G. Gallick (2002)
Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells.Clinical cancer research : an official journal of the American Association for Cancer Research, 8 6
-
M. Szostak, Priti Kaur, Pradip Amin, Stephen Jacobs, Natasha Kyprianou (2001)
Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy.The Journal of urology, 165 6 Pt 1
-
Mark Johnson, M. Robinson, C. Marsh, C. Robson, D. Neal, F. Hamdy (1998)
Expression of Bcl‐2, Bax, and p53 in high‐grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferationThe Prostate, 37
-
M Hanada, C Aime-Sempe, T Sato, JC Reed (1995)
Structure-function analysis of Bcl-2 protein. Identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with BaxJ Biol Chem, 270
-
A. Huang, A. Huang, R. Gandour-Edwards, R. Gandour-Edwards, S. Rosenthal, S. Rosenthal, D. Siders, D. Siders, A. Deitch, A. Deitch, R. White, R. White (1998)
p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy.Urology, 51 2
-
Lukas Bubendorf, Guido Sauter, H. Moch, Paul Jordan, A. Blöchlinger, Th. Gasser, M. Mihatsch (1996)
Prognostic significance of Bcl-2 in clinically localized prostate cancer.The American journal of pathology, 148 5
-
H. Feilotter, M. Nagai, A. Boag, C. Eng, L. Mulligan (1998)
Analysis of PTEN and the 10q23 region in primary prostate carcinomasOncogene, 16
-
D. Roymans, H. Slegers (2001)
Phosphatidylinositol 3-kinases in tumor progression.European journal of biochemistry, 268 3
-
T. Dorai, C. Olsson, A. Katz, R. Buttyan (1997)
Development of a hammerhead ribozyme against bcl‐2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone‐refractory human prostate cancerThe Prostate, 32
-
M. Morris, W. Tong, C. Cordon-Cardo, M. Drobnjak, W. Kelly, S. Slovin, K. Terry, Karen Siedlecki, P. Swanson, M. Rafi, R. DiPaola, N. Rosen, H. Scher (2002)
Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 8 3
-
A. Baldwin (2001)
Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κBJournal of Clinical Investigation, 107
-
Badr Saeed, Haichao Zhang, S. Ng (1997)
Apoptotic program is initiated but not completed in LNCaP cells in response to growth in charcoal‐stripped mediaThe Prostate, 31
-
S. Kreuz, D. Siegmund, P. Scheurich, H. Wajant (2001)
NF-κB Inducers Upregulate cFLIP, a Cycloheximide-Sensitive Inhibitor of Death Receptor SignalingMolecular and Cellular Biology, 21
-
H. Miayake, A. Tolcher, Martin Gleave (2000)
Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides.Journal of the National Cancer Institute, 92 1
-
Jason Gustin, T. Maehama, J. Dixon, D. Donner (2001)
The PTEN Tumor Suppressor Protein Inhibits Tumor Necrosis Factor-induced Nuclear Factor κB Activity*The Journal of Biological Chemistry, 276
-
O. Ozes, L. Mayo, Jason Gustin, S. Pfeffer, L. Pfeffer, D. Donner (1999)
NF-κB activation by tumour necrosis factor requires the Akt serine–threonine kinaseNature, 401
-
H. Muenchen, D. Lin, M. Walsh, E. Keller, K. Pienta (2000)
Tumor Necrosis Factor-α-induced Apoptosis in Prostate Cancer Cells through Inhibition of Nuclear Factor-κB by an IκBα “Super-Repressor”Clinical Cancer Research, 6
-
AV Gasparian (2002)
The role of IKK in constitutive activation of NF-κB transcription factor in prostate carcinoma cellsJ Cell Sci, 115
-
Yosuke Nakajima, A. DelliPizzi, C. Mallouh, N. Ferreri (1996)
TNF‐mediated cytotoxicity and resistance in human prostate cancer cell linesThe Prostate, 29
-
J. Romashkova, S. Makarov (1999)
NF-κB is a target of AKT in anti-apoptotic PDGF signallingNature, 401
-
Timothy Mackey, A. Borkowski, P. Amin, S. Jacobs, N. Kyprianou (1998)
bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer.Urology, 52 6
-
Timothy McDonnel, N. Navone, P. Troncoso, L. Pisters, C. Conti, A. Eschenbach, S. Brisbay, C. Logothetis (1997)
Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer.The Journal of urology, 157 2
-
P. Sant'Agnese (1992)
Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications.Cancer, 70
-
C. Heckman, John Mehew, L. Boxer (2002)
NF-κB activates Bcl-2 expression in t(14;18) lymphoma cellsOncogene, 21
-
H. Suzuki, D. Freije, D. Nusskern, K. Okami, P. Cairns, D. Sidransky, W. Isaacs, G. Bova (1998)
Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.Cancer research, 58 2
-
R. Bookstein, P. Rio, S. Madreperla, F. Hong, Craig ALLREDt, W. Grizzle, Wen-Hwa Lee (1990)
Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma.Proceedings of the National Academy of Sciences of the United States of America, 87
-
S Haldar (1996)
Cancer Res, 56
-
A. Cristofano, P. Pandolfi (2000)
The Multiple Roles of PTEN in Tumor SuppressionCell, 100
-
U. Galderisi, A. Cascino, A. Giordano (1999)
Antisense oligonucleotides as therapeutic agentsJournal of Cellular Physiology, 181
-
M. Sumitomo, M. Tachibana, J. Nakashima, Masaru Murai, Akira Miyajima, F. Kimura, M. Hayakawa, H. Nakamura (1999)
An essential role for nuclear factor kappa B in preventing TNF-alpha-induced cell death in prostate cancer cells.The Journal of urology, 161 2
-
R. Johnstone, A. Ruefli, S. Lowe (2002)
Apoptosis A Link between Cancer Genetics and ChemotherapyCell, 108
-
John Reed (1994)
Bcl-2 and the regulation of programmed cell deathThe Journal of Cell Biology, 124
-
T. McDonnell, P. Troncoso, S. Brisbay, C. Logothetis, Leland Chung, J. Hsieh, S. Tu, M. Campbell (1992)
Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer.Cancer research, 52 24
-
D. Hockenbery, M. Zutter, W. Hickey, M. Nahm, S. Korsmeyer (1991)
BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death.Proceedings of the National Academy of Sciences of the United States of America, 88
-
P. Abrahamsson (1999)
Neuroendocrine differentiation in prostatic carcinomaThe Prostate, 39
-
Y. Tsujimoto, J. Cossman, E. Jaffe, C. Croce (1985)
Involvement of the bcl-2 gene in human follicular lymphoma.Science, 228 4706
-
Sha Lu, S. Tsai, M. Tsai (1999)
Molecular Mechanisms of Androgen-Independent Growth of Human Prostate Cancer LNCaP-AI Cells1.Endocrinology, 140 11
-
K. Chaudhary, P. Abel, E. Lalani (1999)
Role of the Bcl-2 gene family in prostate cancer progression and its implications for therapeutic intervention.Environmental Health Perspectives, 107
-
Y. Umekita, R. Hiipakka, J. Kokontis, S. Liao (1996)
Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride.Proceedings of the National Academy of Sciences of the United States of America, 93 21
-
E Claudio, F Segade, K Wrobel, S Ramos, R Bravo, PS Lazo (1996)
Molecular mechanisms of TNFalpha cytotoxicity: Activation of NF-kappaB and nuclear translocationExp Cell Res, 224
-
Haojie Huang, J. Cheville, Yunqian Pan, P. Roche, L. Schmidt, D. Tindall (2001)
PTEN Induces Chemosensitivity in PTEN-mutated Prostate Cancer Cells by Suppression of Bcl-2 Expression*The Journal of Biological Chemistry, 276
-
B. Duggan, P. Maxwell, J. Kelly, K. Williamson, P. Keane, S. Johnston (2000)
Bcl‐2 proto‐oncogene expression in low‐ and high‐grade prostatic intraepithelial neoplasiaBJU International, 86
-
A Khwaja (1999)
Akt is more than just a Bad kinaseNature, 401
-
D. Scherr, E. Vaughan, John Wei, M. Chung, D. Felsen, Robert Allbright, B. Knudsen (1999)
BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy.The Journal of urology, 162 1
-
M. Davies, D. Koul, Haninder Dhesi, Russell Berman, T. McDonnell, D. McConkey, W. Yung, P. Steck, Cell Biology (1999)
Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN.Cancer research, 59 11
-
CA Heckman, JW Mehew, LM Boxer (2002)
NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cellsOncogene, 21
-
M. Colombel, F. Symmans, Sixtina Gil, K. O'toole, D. Chopin, M. Benson, C. Olsson, S. Korsmeyer, R. Buttyan (1993)
Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers.The American journal of pathology, 143 2
-
KG Leong (2000)
Histol Histopathol., 15
-
E. Claudio, F. Segade, K. Wrobel, S. Ramos, R. Bravo, P. Lazo (1996)
Molecular Mechanisms of TNFa Cytotoxicity: Activation of NF-?B and Nuclear TranslocationExperimental Cell Research
-
K. Fizazi, L. Martinez, C. Sikes, D. Johnston, L. Stephens, T. McDonnell, C. Logothetis, J. Trapman, L. Pisters, N. Ordóñez, P. Troncoso, N. Navone (2002)
The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 8 3
-
D Friedland (1999)
Semin Oncol, 26
-
L Bubendorf (1996)
Am J Pathol, 148
-
N. Craft, Chloe Chhor, C. Tran, A. Belldegrun, J. Dekernion, O. Witte, Jonathan Said, R. Reiter, C. Sawyers (1999)
Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process.Cancer research, 59 19
-
J. Nakashima, M. Tachibana, M. Ueno, A. Miyajima, S. Baba, M. Murai (1998)
Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 4 7
-
John Reed (2000)
Mechanisms of apoptosis.The American journal of pathology, 157 5
-
M. Grossmann, Haojie Huang, D. Tindall (2001)
Androgen receptor signaling in androgen-refractory prostate cancer.Journal of the National Cancer Institute, 93 22
-
S. Catz, J. Johnson (2001)
Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancerOncogene, 20
-
C. Huggins (1967)
Endocrine-induced regression of cancers.American journal of surgery, 136 2
-
I. Apakama, M. Robinson, N. Walter, R. Charlton, J. Royds, C. Fuller, D. Neal, F. Hamdy (1996)
bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer.British Journal of Cancer, 74
-
Suyun Huang, C. Pettaway, H. Uehara, C. Bucana, I. Fidler (2001)
Blockade of NF-κB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasisOncogene, 20
-
T. Maehama, J. Dixon (1998)
The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates the Lipid Second Messenger, Phosphatidylinositol 3,4,5-Trisphosphate*The Journal of Biological Chemistry, 273
-
M. Hanada, C. Aimé-sempé, T. Sato, John Reed (1995)
Structure-Function Analysis of Bcl-2 ProteinThe Journal of Biological Chemistry, 270
-
K. Leong, Aly Karsan (2000)
Signaling pathways mediated by tumor necrosis factor alpha.Histology and histopathology, 15 4
-
D. Koul, Yixin Yao, James Abbruzzese, W. Yung, S. Reddy (2001)
Tumor Suppressor MMAC/PTEN Inhibits Cytokine-induced NFκB Activation without Interfering with the IκB Degradation Pathway*The Journal of Biological Chemistry, 276
-
I. Gray, S. Phillips, Susan Lee, J. Neoptolemos, J. Weissenbach, N. Spurr (1995)
Loss of the chromosomal region 10q23-25 in prostate cancer.Cancer research, 55 21
-
Hong Sun, R. Lesche, Da-ming Li, J. Liliental, Hui Zhang, Jing Gao, Nadia Gavrilova, Brenda Mueller, Xin Liu, Hong Wu (1999)
PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway.Proceedings of the National Academy of Sciences of the United States of America, 96 11
-
R. DiPaola, M. Rafi, V. Vyas, D. Toppmeyer, E. Rubin, J. Patel, S. Goodin, M. Medina, P. Medina, R. Zamek, C. Zhang, E. White, E. Gupta, W. Hait (1999)
Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 7
-
L. Chung (1996)
LNCaP human prostate cancer progression model.Urologic oncology, 2 4
-
George Kulik, Jonathan Carson, Tomáš Vomastek, Kevin Overman, Barry Gooch, S. Srinivasula, E. Alnemri, Gabriel Núñez, Michael Weber (2001)
Tumor necrosis factor alpha induces BID cleavage and bypasses antiapoptotic signals in prostate cancer LNCaP cells.Cancer research, 61 6
-
R. Bookstein, J. Shew, Phang-lang Chen, P. Scully, Wen-Hwa Lee (1990)
Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene.Science, 247 4943
-
E. Hyytinen, G. Thalmann, H. Zhau, R. Karhu, O. Kallioniemi, L. Chung, T. Visakorpi (1997)
Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model.British Journal of Cancer, 75
-
Y. Furuya, S. Krajewski, J. Epstein, John Reed, J. Isaacs (1996)
Expression of bcl-2 and the progression of human and rodent prostatic cancers.Clinical cancer research : an official journal of the American Association for Cancer Research, 2 2
-
Horacio Murillo, Haojie Huang, L. Schmidt, David Smith, D. Tindall (2001)
Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state.Endocrinology, 142 11
-
JA Romashkova, SS Makarov (1999)
NF-kappaB is a target of AKT in anti-apoptotic PDGF signallingNature, 401
-
HJ Muenchen, DL Lin, MA Walsh, ET Keller, KJ Pienta (2000)
Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an IkappaBalpha “super-repressor”Clin Cancer Res, 6
-
Jerry Adams, S. Cory (1998)
The Bcl-2 protein family: arbiters of cell survival.Science, 281 5381
-
J. Lapointe, A. Fournier, V. Richard, C. Labrie (1999)
Androgens down-regulate bcl-2 protooncogene expression in ZR-75-1 human breast cancer cells.Endocrinology, 140 1
-
C. Abate-Shen, M. Shen (2000)
Molecular genetics of prostate cancer.Genes & development, 14 19
-
H. Miyake, A. Tolcher, M. Gleave (1999)
Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model.Cancer research, 59 16
-
C Huggins (1967)
Endocrine-induced regression of cancersCancer Res, 27
-
D. Friedland, J. Cohen, R. Miller, M. Voloshin, R. Gluckman, B. Lembersky, B. Zidar, M. Keating, N. Reilly, B. Dimitt (1999)
A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2.Seminars in oncology, 26 5 Suppl 17
-
S. Denmeade, Xiaohui Lin, J. Isaacs (1996)
Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancerThe Prostate, 28
-
M. Morris, H. Scher (2000)
Novel strategies and therapeutics for the treatment of prostate carcinomaCancer, 89
-
C. Chen, C. Sawyers (2002)
NF-κB Activates Prostate-Specific Antigen Expression and Is Upregulated in Androgen-Independent Prostate CancerMolecular and Cellular Biology, 22
-
M. Taplin, G. Bubley, Y. Ko, E. Small, M. Upton, B. Rajeshkumar, S. Balk (1999)
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.Cancer research, 59 11
-
A. Khwaja (1999)
Apoptosis: Akt is more than just a Bad kinaseNature, 401
-
KS Chaudhary (1999)
Environ Health Perspect, 107
-
H. Perlman, Xuejun Zhang, M. Chen, K. Walsh, R. Buttyan (1999)
An elevated bax/bcl-2 ratio corresponds with the onset of prostate epithelial cell apoptosisCell Death and Differentiation, 6
-
J Lapointe (1999)
Androgens Down-Regulate bcl-2 Protooncogene Expression in ZR-75-1 Human Breast Cancer Cells**This work was supported by a grant from the Canadian Breast Cancer Research Initiative (to C.L.), scholarships from the Fonds de la Recherche en Santé du Québec (to C.L. and J.L.). Additional financial support was provided by Endorecherche.Endocrinology, 140
-
Y. Qiu, D. Robinson, T. Pretlow, H. Kung (1998)
Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells.Proceedings of the National Academy of Sciences of the United States of America, 95 7
-
BJ Feldman (2001)
The development of androgen-independent prostate cancerNature Rev Cancer, 1
-
A. Gross, J. McDonnell, S. Korsmeyer (1999)
BCL-2 family members and the mitochondria in apoptosis.Genes & development, 13 15
-
Jia‐Lun Wang, Dongxiang Liu, Zhijia Zhang, S. Shan, Xiaobing Han, S. Srinivasula, C. Croce, E. Alnemri, Ziwei Huang (2000)
Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells.Proceedings of the National Academy of Sciences of the United States of America, 97 13
-
M. Gleave, J. Hsieh, H. Wu, A. Eschenbach, Leland Chung (1992)
Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.Cancer research, 52 6
-
Jia‐shi Lin, R. Adam, Eric Santiestevan, M. Freeman (1999)
The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells.Cancer research, 59 12
-
A. Gasparian, Y. Yao, D. Kowalczyk, Ludmila Lyakh, A. Karseladze, T. Slaga, I. Budunova (2002)
The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells.Journal of cell science, 115 Pt 1
-
S. Blutt, Timothy McDonnell, T. Polek, Nancy Weigel (2000)
Calcitriol-Induced Apoptosis in LNCaP Cells Is Blocked By Overexpression of Bcl-21.Endocrinology, 141 1
-
A. Raffo, H. Perlman, Min‐Wei Chen, M. Day, Jack Streitman, R. Buttyan (1995)
Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.Cancer research, 55 19
-
M. Krajewska, S. Krajewski, J. Epstein, A. Shabaik, J. Sauvageot, K. Song, S. Kitada, John Reed (1996)
Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers.The American journal of pathology, 148 5
-
H. English, N. Kyprianou, J. Isaacs (1989)
Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castrationThe Prostate, 15
-
D. McConkey, Graham Greene, C. Pettaway (1996)
Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line.Cancer research, 56 24
-
M. McMenamin, P. Soung, S. Perera, I. Kaplan, M. Loda, W. Sellers (1999)
Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage.Cancer research, 59 17
-
M. Tamura, J. Gu, T. Takino, Kenneth Yamada (1999)
Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas.Cancer research, 59 2
-
Pengfei Li, S. Nicosia, Wenlong Bai (2001)
Antagonism between PTEN/MMAC1/TEP-1 and Androgen Receptor in Growth and Apoptosis of Prostatic Cancer Cells*The Journal of Biological Chemistry, 276
-
S. Pugazhenthi, A. Nesterova, C. Sable, K. Heidenreich, L. Boxer, L. Heasley, J. Reusch (2000)
Akt/Protein Kinase B Up-regulates Bcl-2 Expression through cAMP-response Element-binding Protein*The Journal of Biological Chemistry, 275
-
L. Cantley, B. Neel (1999)
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway.Proceedings of the National Academy of Sciences of the United States of America, 96 8
-
BJ Feldman, D Feldman (2001)
The development of androgenindependent prostate cancerNature Rev Cancer, 1
-
C. Boring, Teresa Squires, T. Tong, S. Montgomery (1994)
Cancer statistics, 1994CA: A Cancer Journal for Clinicians, 44
-
MJ Morris (2002)
Clin Cancer Res, 8
-
M. Gleave, A. Tolcher, H. Miyake, C. Nelson, B. Brown, E. Beraldi, J. Goldie (1999)
Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.Clinical cancer research : an official journal of the American Association for Cancer Research, 5 10
-
Xiu-juan Yuan, Y. Whang (2002)
PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathwayOncogene, 21
-
N. Kyprianou (2004)
Apoptosis: therapeutic significance in the treatment of androgen-dependent and androgen-independent prostate cancerWorld Journal of Urology, 12
- Publisher
- Springer Journals
- Copyright
- Copyright © 2003 by Kluwer Academic Publishers
- Subject
- Medicine & Public Health; Cancer Research; Virology; Anatomy; Oncology; Biochemistry, general
- ISSN
- 1360-8185
- eISSN
- 1573-675X
- DOI
- 10.1023/A:1021692801278
- Publisher site
- See Article on Publisher Site
Abstract
Prostate cancer progression and the development of androgen-independent prostate cancer have been largely related to a number of genetic abnormality that affect not only the androgen receptor but also crucial molecules involved in the regulation of survival or apoptotic pathways. One of these molecules, the pro-survival protein BCL-2, has been associated with the development of androgen-independent prostate cancer due to its high levels of expression in androgen-independent tumors in advanced stages of the pathology. The upregulation of BCL-2 after androgen ablation in prostate carcinoma cell lines and in a castrated-male rat model further established a connection between BCL-2 expression and prostate cancer progression. This review focuses on the experimental evidence that associates BCL-2 expression with prostate carcinogenesis and cancer progression, and analyzes the evidence that links the phosphatidylinositol 3-kinase (PI 3-kinase)/nuclear factor kappa B (NF-κB) survival pathway with the upregulation of BCL-2. The way in which hormone ablation influences this survival pathway and the potential application of novel therapeutic strategies to overcome this anti-apoptotic mechanism is examined.
Journal
Apoptosis – Springer Journals
Published: Oct 10, 2004